- Report
- September 2025
- 250 Pages
Global
From €3959EUR$4,490USD£3,447GBP
- Report
- March 2025
- 200 Pages
Global
From €3959EUR$4,490USD£3,447GBP
- Report
- October 2025
- 282 Pages
Global
From €5159EUR$5,850USD£4,492GBP
- Report
- June 2025
- 150 Pages
Global
From €3307EUR$3,750USD£2,879GBP
- Report
- December 2024
- 30 Pages
Global
From €2425EUR$2,750USD£2,111GBP
- Clinical Trials
- April 2025
- 50 Pages
Global
From €1323EUR$1,500USD£1,152GBP
- Report
- June 2025
- 400 Pages
Global
From €4364EUR$4,949USD£3,800GBP
- Report
- September 2025
- 112 Pages
Global
From €3500EUR$4,252USD£3,154GBP
- Report
- May 2021
- 50 Pages
China
From €2293EUR$2,600USD£1,996GBP
- Report
- November 2023
- 135 Pages
Global
From €3527EUR$4,000USD£3,071GBP
- Report
- September 2024
- 343 Pages
Global
From €7011EUR$7,950USD£6,104GBP
- Report
- July 2024
- 150 Pages
Global
From €3307EUR$3,750USD£2,879GBP
- Report
- May 2024
- 137 Pages
Global
From €5731EUR$6,499USD£4,990GBP
- Report
- April 2023
- 117 Pages
Global
From €4189EUR$4,750USD£3,647GBP
- Report
- January 2023
- 85 Pages
Europe
From €1323EUR$1,500USD£1,152GBP
- Report
- March 2023
- 147 Pages
Global
From €4364EUR$4,949USD£3,800GBP
- Report
- January 2024
- 156 Pages
United States
€3351EUR$3,800USD£2,918GBP
- Report
- January 2024
- 114 Pages
United States
€3086EUR$3,500USD£2,687GBP
- Report
- July 2018
- 33 Pages
Global
From €8818EUR$10,000USD£7,678GBP
- Report
- October 2025
- 50 Pages
Global
From €2337EUR$2,650USD£2,035GBP

Tiotropium is a long-acting anticholinergic drug used to treat chronic obstructive pulmonary disease (COPD). It is a bronchodilator, meaning it relaxes the muscles in the airways, allowing more air to flow in and out of the lungs. It is available in both an inhaler and a dry powder inhaler. Tiotropium is the only long-acting anticholinergic approved for the treatment of COPD. It is also used to treat asthma and other respiratory conditions.
Tiotropium is a popular drug in the respiratory drugs market, as it is effective in treating COPD and other respiratory conditions. It is also well-tolerated, with few side effects. It is available in both generic and brand-name forms, making it accessible to a wide range of patients.
Some companies in the Tiotropium market include Boehringer Ingelheim, GlaxoSmithKline, and Novartis. Show Less Read more